NI200700237A - Proceso para la preparación de moduladores de opioides - Google Patents

Proceso para la preparación de moduladores de opioides

Info

Publication number
NI200700237A
NI200700237A NI200700237A NI200700237A NI200700237A NI 200700237 A NI200700237 A NI 200700237A NI 200700237 A NI200700237 A NI 200700237A NI 200700237 A NI200700237 A NI 200700237A NI 200700237 A NI200700237 A NI 200700237A
Authority
NI
Nicaragua
Prior art keywords
preparation
opioid modulators
opioid
modulators
agonists
Prior art date
Application number
NI200700237A
Other languages
English (en)
Inventor
Chaozhong Cai
Wei He
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36646011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200700237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200700237A publication Critical patent/NI200700237A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

La actual invención se refiere a nuevos procesos para la preparación de moduladores de opioides (agonistas y antagonistas) y de los intermedios en su síntesis. Los moduladores de opioides son útiles para el tratamiento y la prevención del dolor y de desordenes gastrointestinales.
NI200700237A 2005-03-14 2007-09-13 Proceso para la preparación de moduladores de opioides NI200700237A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66178405P 2005-03-14 2005-03-14

Publications (1)

Publication Number Publication Date
NI200700237A true NI200700237A (es) 2008-06-25

Family

ID=36646011

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700237A NI200700237A (es) 2005-03-14 2007-09-13 Proceso para la preparación de moduladores de opioides

Country Status (30)

Country Link
US (4) US20060211861A1 (es)
EP (2) EP1858850B1 (es)
JP (3) JP5384933B2 (es)
KR (2) KR101280929B1 (es)
CN (2) CN101175726A (es)
AR (2) AR054745A1 (es)
AU (2) AU2006223394B2 (es)
BR (2) BRPI0607793A2 (es)
CA (2) CA2601674A1 (es)
CR (1) CR9438A (es)
CY (1) CY1116104T1 (es)
DK (1) DK1858850T3 (es)
EA (2) EA014366B1 (es)
ES (1) ES2535048T3 (es)
HR (1) HRP20150417T1 (es)
HU (1) HUE024912T2 (es)
IL (3) IL185974A0 (es)
ME (1) ME02110B (es)
MX (2) MX2007011409A (es)
MY (1) MY145333A (es)
NI (1) NI200700237A (es)
NO (2) NO20075268L (es)
NZ (1) NZ590570A (es)
PL (1) PL1858850T3 (es)
PT (1) PT1858850E (es)
RS (1) RS53873B1 (es)
SI (1) SI1858850T1 (es)
TW (3) TWI500595B (es)
WO (2) WO2006098982A1 (es)
ZA (2) ZA200708810B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
UA86053C2 (ru) * 2004-03-15 2009-03-25 Янссен Фармацевтика Н.В. Соединения как модуляторы опиоидных рецепторов
CA2601674A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica N.V. Process for the preparation of opioid modulators
SG185941A1 (en) * 2007-07-09 2012-12-28 Janssen Pharmaceutica Nv Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
WO2017043626A1 (ja) * 2015-09-11 2017-03-16 株式会社カネカ 光学活性４－カルバモイル－２，６－ジメチルフェニルアラニン誘導体の製造法
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
WO2018055528A2 (en) 2016-09-20 2018-03-29 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
CN106866463B (zh) * 2017-01-24 2018-08-28 富乐马鸿凯（大连）医药有限公司 艾沙度林中间体的制备方法
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
EP4129402A1 (en) 2020-03-31 2023-02-08 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法
CN114507252B (zh) * 2022-02-21 2023-10-27 广西大学 新型芳基硅烷化合物的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5430129A (en) * 1977-08-09 1979-03-06 Mitsubishi Gas Chem Co Inc Preparation of toluic acid amide
JPS5528959A (en) * 1978-08-22 1980-02-29 Sumitomo Chem Co Ltd Production of amide derivative
FR2584401B1 (fr) * 1985-07-04 1987-11-20 Ile De France Nouveau benzamide, son procede de preparation et son application dans le domaine therapeutique
JP2727243B2 (ja) * 1988-12-27 1998-03-11 日本化薬株式会社 ２−アシルアミノ桂皮酸誘導体の製造法
US5684175A (en) * 1993-02-05 1997-11-04 Napro Biotherapeutics, Inc. C-2' hydroxyl-benzyl protected, N-carbamate protected (2R, 3S)- 3-phenylisoserine and production process therefor
JP3493206B2 (ja) * 1993-03-19 2004-02-03 ダイセル化学工業株式会社 光学活性β−アミノ酸類の製法
JP3486922B2 (ja) * 1993-08-23 2004-01-13 住友化学工業株式会社 酸アミドの製造法
AR003108A1 (es) * 1995-01-27 1998-07-08 Novo Nordisk As Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento.
JPH09295939A (ja) * 1995-09-26 1997-11-18 Takeda Chem Ind Ltd リン酸アミド誘導体、その製造法および用途
HUP0101467A3 (en) * 1998-03-11 2003-03-28 G D Searle & Co Skokie Halogenated amidino amino acid derivatives useful as nitric monoxide synthase inhibitors
EP1055665B1 (en) * 1999-05-28 2003-10-22 Pfizer Products Inc. 3-(3-Hydroxyphenyl)-3-amino-propionamide derivatives
SK6282003A3 (en) * 2000-10-30 2004-02-03 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7041681B2 (en) * 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
UA86053C2 (ru) * 2004-03-15 2009-03-25 Янссен Фармацевтика Н.В. Соединения как модуляторы опиоидных рецепторов
CA2601674A1 (en) * 2005-03-14 2006-09-21 Janssen Pharmaceutica N.V. Process for the preparation of opioid modulators

Also Published As

Publication number Publication date
EA014366B1 (ru) 2010-10-29
AU2006223394B2 (en) 2012-10-18
MX2007011409A (es) 2008-02-22
ES2535048T3 (es) 2015-05-04
NO20075269L (no) 2007-12-10
US20100152460A1 (en) 2010-06-17
CA2601674A1 (en) 2006-09-21
KR20070112255A (ko) 2007-11-22
US20060211861A1 (en) 2006-09-21
CY1116104T1 (el) 2017-02-08
WO2006099060A3 (en) 2006-11-02
CA2601481C (en) 2013-11-12
TW200716548A (en) 2007-05-01
JP2008533141A (ja) 2008-08-21
AR054745A1 (es) 2007-07-11
EP1863764A1 (en) 2007-12-12
CR9438A (es) 2008-09-09
IL185972A (en) 2013-07-31
TWI414518B (zh) 2013-11-11
PL1858850T3 (pl) 2015-06-30
MX2007011412A (es) 2008-02-22
SI1858850T1 (sl) 2015-04-30
IL209402A (en) 2015-06-30
TW200700388A (en) 2007-01-01
JP2008533143A (ja) 2008-08-21
IL209402A0 (en) 2011-01-31
BRPI0607793A2 (pt) 2009-06-13
ZA200708810B (en) 2009-01-28
WO2006098982A1 (en) 2006-09-21
JP5802242B2 (ja) 2015-10-28
TWI500595B (zh) 2015-09-21
ME02110B (me) 2015-10-20
WO2006099060A2 (en) 2006-09-21
AR053170A1 (es) 2007-04-25
EP1858850B1 (en) 2015-01-21
CN101175726A (zh) 2008-05-07
HUE024912T2 (en) 2016-02-29
ZA200708809B (en) 2009-03-25
CN101175725B (zh) 2011-02-02
KR101280929B1 (ko) 2013-07-01
KR20070116067A (ko) 2007-12-06
EA200701979A1 (ru) 2008-04-28
US20060211863A1 (en) 2006-09-21
NZ590570A (en) 2012-06-29
JP2013234192A (ja) 2013-11-21
NO340604B1 (no) 2017-05-15
JP5384933B2 (ja) 2014-01-08
RS53873B1 (en) 2015-08-31
US20100036132A1 (en) 2010-02-11
NO20075268L (no) 2007-12-10
PT1858850E (pt) 2015-02-24
IL185974A0 (en) 2008-01-06
BRPI0607792A2 (pt) 2009-06-13
EA015512B1 (ru) 2011-08-30
CA2601481A1 (en) 2006-09-21
DK1858850T3 (en) 2015-02-09
AU2006223482A1 (en) 2006-09-21
EP1858850A2 (en) 2007-11-28
US7629488B2 (en) 2009-12-08
MY145333A (en) 2012-01-31
EA200701978A1 (ru) 2008-04-28
CN101175725A (zh) 2008-05-07
TW201302676A (zh) 2013-01-16
HRP20150417T1 (en) 2015-09-25
AU2006223394A1 (en) 2006-09-21
IL185972A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
NI200700237A (es) Proceso para la preparación de moduladores de opioides
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
ATE469897T1 (de) Indazolcarbonsäureamidverbindungen
CL2008002268A1 (es) Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
CR10138A (es) 1h indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
TW200745024A (en) Carboxamide derivatives as muscarinic receptor antagonists
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
PE20141062A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
CL2007003110A1 (es) Compuestos derivados de ciclohexilamida, moduladores de los receptores de serotonina 5-ht2a y dopamina d3; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos cognitivos, adiccion a las drogas, depresi
UY29734A1 (es) Piperazinas bicíclicas como antagonistas de receptores de glutamato metabotrópicos
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
CL2010001429A1 (es) Compuestos derivados de piperazinilo, moduladores del receptor p75ntr de neurotrofinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades neurodegenerativas centrales y perifericas, depresion, afecciones cardiovasculares y cancer.
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
CL2007001715A1 (es) Compuestos derivados de benzoimidazol sustituidos, agonistas del receptor cb1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratatmiento del dolor, sindrome de colon irritable, ansiedad, cancer, enfermedad de parkinson, entre otras.
CL2012000102A1 (es) Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras.
UY30089A1 (es) Antagonistas del receptor de urotensina-ii